News Release

Noni plant may yield new drugs to fight tuberculosis

Peer-Reviewed Publication

American Chemical Society

Click here for abstract.

HONOLULU, Dec. 18 - Known to herbalists for its healing powers, the native Hawaiian noni plant has been found to kill the bacterium that causes tuberculosis. The finding could lead to new drugs to fight the disease, according to research presented here today during the 2000 International Chemical Congress of Pacific Basin Societies. Tuberculosis has resurfaced recently due to the emergence of drug-resistant strains, and is particularly prevalent in Hawaii.

The weeklong scientific meeting, held once every five years, is hosted by the American Chemical Society, in conjunction with its counterparts in Australia, Canada, Japan and New Zealand.

Noni, also known as Indian mulberry or its scientific name, Morinda citrifolia, is an evergreen plant that is recognized by its foul-smelling, green-skinned fruit. It is found throughout the world, particularly in Asia and northern Australia. Hawaii is the major source of noni in the United States.

While traditional Hawaiian healers have long used the plant to treat patients afflicted with tuberculosis (TB), this study represents the first report identifying the compounds that may be responsible for this action, according to researchers at the University of Santo Tomas (UST), Manila, Philippines.

The researchers randomly screened a group of native plants for potential activity against Mycobacterium tuberculosis, the bacterium that causes TB. In laboratory tests, a concentration of extracts from the leaves of the noni showed a significant inhibitory rate, killing 89 percent of the pathogens, they say. This compares favorably with rifampicin, a drug commonly used to treat TB, which has an inhibition rate of 97 percent at the same concentration, according to the researchers.

The active compounds were isolated from the extract and found to be phytosterols (plant steroids). The compounds are structurally different from those drugs that are typically used to treat TB, indicating that the compounds may act under a different mechanism that could be useful for building an alternative drug to fight resistant bacterial strains, the researchers say. An additional drug source could also provide cheaper alternatives to more expensive drugs for treating TB, they add.

"I hope that pharmaceutical companies will pay attention to this research and explore the noni plant as a potential source of drugs," says Jonel Saludes, who was the lead researcher on the study when he was a graduate student at UST. He is currently an assistant professor in the department of chemistry at the University of San Agustin, Iloilo City, Philippines, and is pursuing his Ph.D.

Saludes declined to speculate how much of the extract is needed to achieve a therapeutic effect in humans, as the extract has not yet been tested in animals. Also unknown is whether the active chemicals are found in other parts of the plant, including the fruit, stems and roots. Studies on the fruit are ongoing, he says.

The noni plant has been used for hundreds of years to treat a variety of other illnesses, including heart disease, diabetes and cancer. The plant's popularity has recently surged in the United States and Southeast Asia. The noni's fruit has been processed into juices, pills and other products that are sold in health food stores and over the Internet.

Like other herbal remedies, the curative powers of noni remain largely unproven, while its potential health risks are unknown. Still, the plant has become the target of a growing number of studies.

The incidence of tuberculosis is increasing worldwide, due largely to the emergence of drug- resistant bacteria. In 1999, Hawaii had the highest rate of TB in the nation, according to the Centers for Disease Control and Prevention. Unless improved efforts are undertaken to stem the growing threat worldwide, the disease will continue to rise, health officials warn.

More than 8,000 research papers will be presented during this year's International Chemical Congress, which is sponsored jointly by the American Chemical Society, the Chemical Society of Japan, the Canadian Society of Chemistry, the Royal Australian Chemical Institute and the New Zealand Institute of Chemistry.

###

The poster on this research, ORGN 1337, will be presented at 9 a.m., Monday, Dec. 18, at the Hilton Hawaiian Village, Coral Ballroom III, Mid-Pacific Conference Center, during the symposium, "Natural Products of Chemistry: Biological Activity and Synthesis."

Jonel Saludes is an assistant professor in the department of chemistry at the University of San Agustin in Iloilo City, Philippines.

The study was funded by the Philippine government, the International Foundation for Science, and the United Nations Educational, Scientific and Cultural Organization (UNESCO).


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.